ArticleActa pharmacologica Sinica2026
Time-resolved proteomic and phosphoproteomic analysis reveals convergent and divergent biological perturbations induced by FDA-approved CDK4/6 inhibitors in hormone receptor-positive breast cancers.
Shi-Yu Duan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.